OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone(510) 775-0515
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) announced its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.10). View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
5 analysts have issued twelve-month price objectives for OncoCyte's stock. Their predictions range from $6.00 to $8.00. On average, they anticipate OncoCyte's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 246.5% from the stock's current price. View Analyst Price Targets for OncoCyte.
What is the consensus analysts' recommendation for OncoCyte?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.
Has OncoCyte been receiving favorable news coverage?
News headlines about OCX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoCyte earned a news impact score of 0.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for OncoCyte.
Are investors shorting OncoCyte?
OncoCyte saw a drop in short interest in August. As of August 15th, there was short interest totalling 1,007,700 shares, a drop of 18.8% from the July 15th total of 1,240,400 shares. Based on an average daily trading volume, of 365,900 shares, the short-interest ratio is currently 2.8 days. Approximately 3.3% of the company's stock are short sold. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Paradigm Biopharmaceuticals (PAR), ProMetic Life Sciences (PLI), Rafael (RFL), CEL-SCI (CVM), Pfenex (PFNX), 22nd Century Group (XXII), Emerald Health Therapeutics (EMH), Botanix Pharmaceuticals (BOT), Emblem (EMC), Acasti Pharma (ACST), Monash IVF Group (MVF), Senesco Technologies (ELOX), Enochian Biosciences (ENOB), Horizon Discovery Group (HZD) and IMV (IMV).
What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 65)
- Mr. Mitchell S. Levine, Chief Financial Officer
- Dr. Lyndal K. Hesterberg, Chief Scientific Officer
- Mr. Albert P. Parker II, Chief Operating Officer
- Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)
Who are OncoCyte's major shareholders?
OncoCyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.58%), BlackRock Inc. (2.99%), Vanguard Group Inc. (2.72%), Maven Securities LTD (0.41%), Bank of New York Mellon Corp (0.15%) and Northern Trust Corp (0.14%). Company insiders that own OncoCyte stock include Biotime Inc, Broadwood Partners, LP and Mitchell S Levine. View Institutional Ownership Trends for OncoCyte.
Which major investors are selling OncoCyte stock?
Which major investors are buying OncoCyte stock?
OCX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Maven Securities LTD, Vanguard Group Inc., Jane Street Group LLC, Bank of New York Mellon Corp, Doheny Asset Management CA, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. Company insiders that have bought OncoCyte stock in the last two years include Broadwood Partners, LP and Mitchell S Levine. View Insider Buying and Selling for OncoCyte.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $2.02.
How big of a company is OncoCyte?
What is OncoCyte's official website?
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.
MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
